How Long Does Interferon Stay in Your System? What the Pharmacokinetic Literature Reports

Short answer, and what the cited literature actually supports

There is no single "interferon half-life." Interferon is a family of signalling proteins — type I (including interferon-α, -β and the estrogen-induced interferon-ε described by researchers who reported that Neisseria gonorrhoeae uniquely exploits interferon-ε via effects on sialic acid metabolism, PMID 40494348), type II (interferon-γ) and type III (the interferon-λ family, one member of which was the subject of a study that measured pharmacokinetic parameters of an orally administered pegylated interferon-λ1 preparation, PMID 35737159). Each subtype, and each pharmaceutical formulation of it, behaves differently in the body.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or laboratory testing. Nothing here describes how any product should be used, and no numeric half-life, dose or clearance window is invented where the verified literature summarised below does not report one.

Why "how long does it stay in your system" is three separate questions

Pharmacology separates questions that everyday language blurs together. For a protein like interferon they are:

1. How long is the administered protein measurable in plasma? This is pharmacokinetics — absorption, distribution, metabolism and elimination. The study that reported pharmacokinetic parameters for oral pegylated interferon-λ1 addressed exactly this kind of question for that specific preparation (PMID 35737159).
2. How long does the downstream biological signal persist? Interferon acts by binding receptors and switching on interferon-stimulated genes, and researchers reported that type I interferon-dependent IFIT3 signalling was critical for viral clearance in airway neutrophils (PMID 36993474). Gene-expression signals can outlast measurable drug.
3. Can anyone detect that interferon was administered? This is an assay question, complicated by the fact that the body makes interferons continuously — a point illustrated by work on human ZNFX1 deficiency, where researchers described multisystem inflammation and susceptibility to viral infections (PMID 33872655).

Compound-specific pharmacokinetic evidence

Directly measured PK

Within the verified literature summarised on this page, the single study that explicitly reported pharmacokinetic parameters was the 2022 report on oral pegylated interferon-λ1 (PMID 35737159). That work is compound- and route-specific: it describes a pegylated type III interferon given by mouth, not injected interferon-α, and its parameters cannot be transferred to other subtypes or routes. Because the numeric values are not reproduced here, readers looking for figures are directed to the primary paper rather than to a second-hand number.

Pegylation and treatment regimens

Pegylation — attaching polyethylene glycol chains to a protein — is the standard pharmaceutical strategy for extending a protein's residence time, and pegylated and non-pegylated interferons have been discussed as distinct monotherapy regimens in the clinical literature (PMID 25764683). In hepatitis B, a 2022 review in the Journal of Hepatology examined strategies for functional cure including stopping nucleos(t)ide analogues and adding interferon (PMID 35589248) — a reminder that interferon is generally studied as a multi-week course, so "how long it stays in your system" after a single administration is a different question from how long a course of therapy influences a disease process.

Exposure modelling drives dosing intervals

Where a biologic's exposure has been characterised, that characterisation is what determines how often it is given in trials. Researchers described dose regimen selection for a phase 3 trial of anifrolumab in lupus nephritis (PMID 42175562); anifrolumab is a monoclonal antibody directed at the type I interferon receptor rather than an interferon itself, and antibodies have very different elimination behaviour from small cytokines, so it is cited here only as an example of how exposure modelling underpins regimen choice — not as interferon pharmacokinetic data.

General protein and peptide pharmacology (clearly labelled as general)

The following points are general protein-drug pharmacology, not findings from the interferon papers cited above. They are included because they explain why interferon PK varies so widely between products:

• Size and filtration. Small proteins below the renal filtration threshold are cleared rapidly by the kidney; increasing hydrodynamic size (for example with polyethylene glycol) slows that route.
• Proteolysis. Proteins are broken down to amino acids by peptidases in plasma, tissue and the gut, so there is no long-lived chemical residue analogous to a small-molecule metabolite.
• Receptor-mediated uptake. Cytokines are internalised with their receptors, meaning clearance can depend on how many receptors are available — a target-mediated component that is not constant across doses.
• Route. Subcutaneous and intramuscular administration produce slower absorption and lower peak concentrations than intravenous administration; oral delivery of a protein requires protection from digestion, which is why the oral pegylated interferon-λ1 work needed its own pharmacokinetic characterisation (PMID 35737159).
• The five-half-life convention. Pharmacology conventionally treats a drug as essentially eliminated after roughly five elimination half-lives. That is arithmetic, not an interferon-specific finding, and it is only usable if a half-life for the specific product is known.

Formulation and delivery change where a molecule goes

Distribution, not just elimination, determines what "in your system" means. A 2025 study described a nanomedicine engineered to penetrate the blood–pancreas barrier for treatment of acute pancreatitis (PMID 39950925) — a non-interferon example showing that carrier design can direct a biologic into tissue compartments it would otherwise reach poorly. Similarly, researchers reported that intratumoral T cell activation killed tumours regardless of T cell specificity (PMID 42711529), illustrating that local immune activation studies are designed around local exposure rather than systemic plasma levels.

Drug presence versus biological effect

The gap between these two is unusually wide for interferons. Researchers reported that interferon signalling in the nasal epithelium distinguished among lethal and common-cold coronaviruses and mediated viral clearance (PMID 38758698), and a separate group reported that type I interferon-dependent IFIT3 signalling was critical for viral clearance in airway neutrophils (PMID 36993474). In both cases the measured endpoint was a transcriptional and antiviral response, which follows receptor engagement and can persist after circulating protein has fallen below assay limits.

The word "clearance" itself is ambiguous in this field. In a 2017 study, researchers reported that interferon-alpha-induced hepatitis C virus clearance restored p53 tumour suppressor function more than direct-acting antivirals did (PMID 29404458) — there, "clearance" meant elimination of the virus, not elimination of the drug. Readers comparing sources should check which meaning is intended.

Detectability and drug testing: what is and is not tested for

Stated plainly:

• Standard workplace urine panels do not test for interferon. Five- and ten-panel immunoassays are designed for small molecules of abuse — amphetamines, cannabinoids, cocaine metabolites, opioids, phencyclidine and similar classes. Protein biologics are not part of those panels, and a protein would not produce a signal on them.
• Routine clinical chemistry does not measure interferon. Standard blood panels report electrolytes, liver enzymes, blood counts and similar analytes, not cytokine concentrations.
• Interferon is measured in medicine — but usually the body's own. Interferon-γ release assays quantify interferon-γ produced by a person's own lymphocytes after antigen stimulation; a 2026 review addressed diagnosis and management of tuberculosis infection, the setting in which such testing is routine (PMID 42191344). Those assays report host immune response, not administration of a pharmaceutical interferon.
• Endogenous background complicates any "detection" claim. Interferons are produced physiologically and under hormonal control, as in the estrogen-induced interferon-ε characterised by researchers studying Neisseria gonorrhoeae (PMID 40494348), and interferon-related pathways are dysregulated in inherited conditions such as ZNFX1 deficiency, where multisystem inflammation and viral susceptibility were described (PMID 33872655). Distinguishing administered from endogenous interferon is a specialised laboratory problem, not a routine test.

Factors reported or expected to change clearance

Tolerability and systemic effects: What Studies Report

The verified papers summarised here were not designed as safety studies, and no adverse-event rates are quoted for that reason. What they do show is that interferon signalling is systemic and inflammatory in character: researchers reported multisystem inflammation together with susceptibility to viral infections in human ZNFX1 deficiency, a disorder of interferon-related immune regulation (PMID 33872655), and a 2022 hepatology review weighed adding interferon against other strategies when discussing how to achieve functional cure of hepatitis B (PMID 35589248). Clinical interferon products are prescription medicines whose labelled warnings are set by regulators, and those documents — not this page — are the source for tolerability information.

Limitations of this summary

Only one paper in the verified set reported pharmacokinetic parameters directly, and it concerned an oral pegylated interferon-λ1 preparation (PMID 35737159). Everything else cited here describes interferon biology, disease context or downstream signalling rather than drug elimination. Any single number presented elsewhere as "the" interferon half-life should be checked against the specific product, subtype, route and population in which it was measured.

Related reading

• Interferon: what the literature covers
• How long do peptides stay in your system?

References

• Pharmacokinetic Parameters of Oral Pegylated IFN-λ1 (Bulletin of Experimental Biology and Medicine, 2022)
• [PEG-IFN/IFN monotherapy] (Nihon Rinsho. Japanese Journal of Clinical Medicine, 2015)
• How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development? (Journal of Hepatology, 2022)
• Interferon-alpha-induced hepatitis C virus clearance restores p53 tumor suppressor more than direct-acting antivirals (Hepatology Communications, 2017)
• Interferon signaling in the nasal epithelium distinguishes among lethal and common cold coronaviruses and mediates viral clearance (PNAS, 2024)
• Type I interferon-dependent IFIT3 signaling is critical for viral clearance in airway neutrophils (Research Square, 2023)
• Interferon-epsilon, an estrogen-induced type I interferon, is uniquely exploited by Neisseria gonorrhoeae via effects on sialic acid metabolism (Cell Host & Microbe, 2025)
• Multisystem inflammation and susceptibility to viral infections in human ZNFX1 deficiency (The Journal of Allergy and Clinical Immunology, 2021)
• Tuberculosis Infection: Diagnosis and Management (Cold Spring Harbor Perspectives in Medicine, 2026)
• Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis (Clinical Pharmacology and Therapeutics, 2026)
• Nanomedicine Penetrating Blood-Pancreas Barrier for Effective Treatment of Acute Pancreatitis (Advanced Science, 2025)
• Intratumoral T cell activation kills tumors regardless of T cell specificity (Nature Immunology, 2026)